About IGF-1 and LR3 IGF-1
IGF-1 and its analogs have been independently investigated for their potential effects on a variety of conditions for many years now, but physicians have had limited opportunities to obtain and prescribe reliably sourced material in a format that is clinically practical. Until now.
FDA-registered manufacturers produce the IGF-1 and LR3 IGF-1 molecules through a proprietary recombinant process, and licensed domestic pharmacists compound it for self-administration.
As with any medication, physicians should be well informed about the product they prescribe and base any use on firm scientific rationale and sound medical evidence.
IGF-1
Insulin-like growth factor-1 is a naturally occurring protein with a molecular structure similar to insulin. It is produced inside the body primarily by the liver as an endocrine hormone, and it functions as a mediator of the effects of growth hormone.
When growth hormone is released into the bloodstream from the pituitary gland, it stimulates the liver to produce IGF-1, which in turn stimulates growth in a broad range of cells: skeletal, muscle, cartilage, bone, nerve, skin and multiple organs.
Currently, IGF-1 (mecasermin [rDNA origin]) is FDA approved for the treatment of growth failure in children with severe primary IGF-1 deficiency, or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. A number of peer reviewed, independent investigational studies are currently evaluating the clinical application of IGF-1 in relation to additional conditions.
Please keep in mind that regardless of the conclusions of any peer reviewed, independent investigational studies, the off-label prescribing of a medical product cannot be considered safe or effective for a particular use.
For more information on IGF-1, please visit the PubMed.gov database.
LR3 IGF-1
LR3 IGF-1 is an 83 amino acid analog of IGF-1 that comprises the complete human IGF-1 sequence with the substitution of an Arg(R) for the Glu(E) at position 3 and a 13 amino acid extension peptide at the N terminus.
It is important to note that LR3 IGF-1 has not been approved by the FDA to treat any disease condition, and the off-label prescribing of a medical product cannot be considered safe or effective for a particular use.
For more information on LR3 IGF-1, please visit the PubMed.gov database.
